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CD4+ T helper (Th) cells differentiate into dis-
crete subsets, which can be discriminated on 
the basis of their cytokine expression profiles. 
Besides the “classical” CD4+ T cell subsets   
(i.e., Th1, Th2, and regulatory T cells), a new 
subset characterized by secretion of IL-17 was 
identified (Harrington et al., 2005; Park et al., 
2005). Th17 cells provide protection in certain 
infections,  but  more  importantly,  have  been 
linked to development of autoimmunity, a 
function  previously  assigned  to  Th1  cells 
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T helper cells secreting interleukin (IL)-17 (Th17 cells) play a crucial role in autoimmune 
diseases like multiple sclerosis (MS). Th17 differentiation, which is induced by a combina-
tion of transforming growth factor (TGF)-/IL-6 or IL-21, requires expression of the 
transcription factor retinoic acid receptor–related orphan receptor t (RORt). We 
identify the nuclear receptor peroxisome proliferator–activated receptor  (PPAR) as a 
key negative regulator of human and mouse Th17 differentiation. PPAR activation in 
CD4+ T cells selectively suppressed Th17 differentiation, but not differentiation into Th1, 
Th2, or regulatory T cells. Control of Th17 differentiation by PPAR involved inhibition of 
TGF-/IL-6–induced expression of RORt in T cells. Pharmacologic activation of PPAR 
prevented removal of the silencing mediator for retinoid and thyroid hormone receptors 
corepressor from the RORt promoter in T cells, thus interfering with RORt transcrip-
tion. Both T cell–specific PPAR knockout and endogenous ligand activation revealed the 
physiological role of PPAR for continuous T cell–intrinsic control of Th17 differentiation 
and development of autoimmunity. Importantly, human CD4+ T cells from healthy controls 
and MS patients were strongly susceptible to PPAR-mediated suppression of Th17 
differentiation. In summary, we report a PPAR-mediated T cell–intrinsic molecular 
mechanism that selectively controls Th17 differentiation in mice and in humans and that 
is amenable to pharmacologic modulation. We therefore propose that PPAR represents a 
promising molecular target for specific immunointervention in Th17-mediated autoim-
mune diseases such as MS.
© 2009 Klotz et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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We therefore determined the frequency of antigen-specific 
Th17 cells in the CNS by ELISpot. After MOG35-55-peptide   
specific stimulation of equal numbers of CNS-derived T cells, 
we  observed  a  strong  reduction  in  antigen-specific  IL-17 
producing, but interestingly not IFN- producing, CD4+ 
T cells (Fig. 1). In light of these results, we next investigated 
the influence of PPAR on CD4+ Th differentiation. To focus 
exclusively on the effect of PPAR in T cells, we used stimu-
lation with CD3/CD28 in the absence of antigen-presenting 
cells. Interestingly, PPAR activation by PIO selectively in-
hibited Th17 differentiation induced by TGF- and IL-6, 
whereas IL-12–induced Th1 differentiation was completely 
unaffected (Fig. 1 d; Fig. S1). To obtain unequivocal evidence 
for the role of PPAR for Th17 differentiation, we generated 
T cell–specific PPAR knockout mice by crossing CD4-Cre 
mice with mice carrying loxP sites within the PPAR gene 
(CD4-PPARKO; Fig. S2). In the absence of PPAR, Th17 
differentiation was strongly increased when compared with 
wild-type CD4+ T cells (Fig. 1 d), indicating that PPAR 
serves as a T cell–intrinsic brake of Th17 differentiation un-
der physiological conditions. Accordingly, Th1 differentiation 
was not altered in CD4-PPARKO T cells (Fig. 1 d). Interest-
ingly, the endogenous PPAR agonist 13s-HODE, a linoleic 
acid derivative (Huang et al., 1999), equally suppressed Th17, 
but not Th1, differentiation (Fig. 1 d), further indicating that 
PPAR activity limits Th17 differentiation under physiologi-
cal conditions. Given the fact that 12/15-lipoxygenase is 
expressed in T cells (Vanderhoek, 1988), it is reasonable to 
assume that endogenous ligands produced by T cells them-
selves serve as a brake for Th17 differentiation in an autocrine 
fashion. Also, PPAR ligand production by antigen-presenting 
cells may contribute to local control of Th17 differentiation 
(Huang et al., 1999).
We further substantiated the inhibitory effect of PPAR 
on Th17 differentiation by investigating other classical mark-
ers  of  Th17  cells.  In  addition  to  IL-17A,  we  found  that 
PPAR activation by PIO suppressed expression of TNF and 
IL-22 (Fig. 1 e), as well as IL-17F, IL-21, and IL-23R, in   
T cells (Fig. 1 f). Likewise, expression of the chemokine re-
ceptor CCR6 and its ligand CCL20 were also strongly con-
trolled by PPAR activation (Fig. 1 g). This demonstrates 
that PPAR, indeed, influenced differentiation of Th17 cells 
rather than merely suppressing IL-17A production.
Selectivity of PPAR for Th17 differentiation
To further characterize the specificity of PPAR on the 
differentiation of Th17 cells, we evaluated the effect of PIO 
on cytokine-induced CD4+ T cell differentiation into Th1, 
Th2, or regulatory T cells. Importantly, PIO did not modu-
late TGF-–mediated induction of Foxp3+ regulatory T 
cells,  IL-4–mediated  induction  of  Th2  cells,  or  IL-12–
  mediated induction of Th1 cells (Fig. 2 a). This is in contrast 
to the effect of RA, which is a natural ligand of the nuclear 
RA receptor (Chambon, 1994) that has been shown to re-
ciprocally regulate Th17 and regulatory T cell differentia-
tion (Mucida et al., 2007). In direct comparison, RA and 
(Bettelli et al., 2007). Th17 cells mediate pathology in sev-
eral mouse models of autoimmunity, such as experimental 
autoimmune encephalomyelitis (EAE), inflammatory bowel 
disease,  and  collagen-induced  arthritis  (Cua  et  al.,  2003; 
Murphy et al., 2003; Yen et al., 2006). Recent studies have 
addressed the role of Th17 cells in human autoimmunity 
(Lock et al., 2002; Tzartos et al., 2008). Th17 differentiation 
critically depends on TGF-, together with proinflammatory 
cytokines such as IL-6 or IL-21 (Ivanov et al., 2006; Yang et 
al., 2008). The key transcription factor for Th17 differentia-
tion is retinoic acid (RA) receptor–related orphan receptor t 
(RORt; Ivanov et al., 2006; Manel et al., 2008). However, 
little  information  exists  on  the  T  cell–intrinsic  molecular 
mechanisms controlling RORt activity, thus contributing 
to control of Th17-mediated autoimmunity.
We and others have previously shown that the nuclear 
receptor peroxisome proliferator–activated receptor  (PPAR) 
is a negative regulator of dendritic cell maturation and func-
tion, thereby contributing to CD4+ T cell anergy in vivo 
(Klotz et al., 2007; Szatmari et al., 2007). PPAR has also 
been reported to influence the function of Th cell clones 
(Clark et al., 2000); however, the influence of PPAR on Th 
differentiation has not yet been addressed. Upon ligand bind-
ing, PPAR heterodimerizes with the retinoid X receptor 
and binds to the PPAR response elements (PPRE) located in 
the promotor region of target genes (Pascual et al., 2005; 
Glass and Ogawa, 2006). Additionally, the antiinflammatory 
effects of PPAR are mediated by negative interference with 
proinflammatory cell signaling, e.g., stabilization of corepres-
sor complexes, such as nuclear corepressor (NCoR) and si-
lencing mediator for retinoid and thyroid hormone receptors 
(SMRT; Pascual et al., 2005; Straus and Glass, 2007). PPAR 
agonists include endogenous ligands such as the linoleic acid 
derivative  13s-hydroxyoctadecadienoic  acid  (HODE)  pro-
duced by 12/15-lipoxygenase, as well as several synthetic 
agonistic ligands such as the antidiabetic thiazolidinediones, 
e.g., pioglitazone (PIO; Huang et al., 1999; Straus and Glass, 
2007). Previous studies demonstrated a beneficial role of 
PPAR in EAE (Niino et al., 2001; Diab et al., 2002;   
Feinstein et al., 2002). These findings prompted us to address 
the question of whether PPAR is involved in the T cell–
  intrinsic control of Th17 responses.
RESULTS AND DISCUSSION
Control of Th17 differentiation by PPAR
We first investigated the influence of PPAR on the Th17 
responses during MOG-induced EAE. Pharmacological acti-
vation of PPAR with PIO in vivo ameliorated the disease 
course over the entire observation period (Fig. 1 a), as previ-
ously reported (Niino et al., 2001; Diab et al., 2002; Feinstein 
et al., 2002). Importantly, CD4+ T cells isolated from the 
central nervous system (CNS) of PIO-treated EAE mice at 
day  17  after  disease  induction  produced  significantly  less   
IL-17A after PMA/ionomycin restimulation (Fig. 1 b). This 
prompted us to investigate in more detail the influence of 
PPAR on the function of autoreactive MOG-specific T cells. JEM VOL. 206, September 28, 2009  2081
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ported (Iwata et al., 2003). Collectively, these data indicate 
that distinct molecular mechanisms were involved in PPAR-
mediated, as compared with RA-mediated, control of T 
cell differentiation.
We next investigated whether PPAR also affected expres-
sion of the key transcription factors determining CD4+ T cell 
differentiation. PPAR-activation selectively suppressed TGF-
/IL-6–mediated expression of RORt, the transcription factor 
PIO both efficiently suppressed Th17 differentiation, whereas 
RA but not PIO induced TGF-–mediated expression of 
Foxp3 (Fig. 2 a). Accordingly, CD4-PPARKO T cells did 
not show altered TGF-–mediated Foxp3-induction (un-
published data). A further distinction between RA and PIO 
was observed on Th1 differentiation, as RA slightly but sig-
nificantly impeded IL-12–mediated induction of IFN- 
expression in T cells (Fig. 2 a), as has been previously re-
Figure 1.  Control of Th17 differentiation by PPAR. (a) MOG-EAE was induced in PIO or vehicle-treated wild-type mice (n = 6 per group, 3 experi-
ments), and the clinical disease score was assessed daily. (b) In a separate experiment, mice were sacrificed at the peak of disease (day 18), CD4+ T cells 
were isolated from the CNS, restimulated with PMA/ionomycin, and analyzed by flow cytometry gated on CD4+ T cells; representative dot plots and mean 
results ± SEM from four animals per group are shown; data are from two experiments. (c) CD4+ T cells from the CNS were restimulated with MOG35-55-
loaded DCs, and numbers of IL-17 and of IFN-–producing cells per 3 × 104 CD4+ T cells were determined by ELISpot analysis. Graphs denote mean ± SEM 
of all animals (n = 6 per group, 2 experiments). (d) Purified CD4+ T cells from CD4-PPARKO mice or WT littermates were treated with PIO or the endog-
enous PPAR agonist 13s-HODE, and Th17 differentiation was induced by stimulation for 72 h (top row). Alternatively, Th1 differentiation was induced 
for 72 h (bottom row). Cytokine-producing cells were determined by flow cytometry after PMA/ionomycin restimulation. Only living cells were analyzed 
by using LIVE/DEAD stain and exclusion of autofluorescence (x axis). Numbers denote mean percentage ± SEM. (e) Th17 differentiation was induced as 
above and TNF, IL-17A, and IL-22 expression were determined by flow cytometry. Numbers denote mean percentage ± SEM. (f) Th17 differentiation was 
induced as above; after 72 h expression of IL-17A, IL-17F, IL-21, and IL-23R were measured by quantitative real-time RT-PCR normalized to -actin levels. 
(g) Additionally, CCR6-expression was determined by flow cytometry; CCL20-release was assessed by ELISA. (d–g) One out of at least three independent 
experiments is shown.2082 PPAR INHIBITS TH17 DIFFERENTIATION | Klotz et al.
2008). Furthermore, several groups have reported that the 
aryl hydrocarbon receptor elicits either regulatory T cell or 
Th17 responses when activated by distinct ligands; however, 
the underlying mechanisms do not seem to involve RORt 
regulation (Quintana et al., 2008; Veldhoen et al., 2008). Ad-
ditionally, the nuclear orphan receptor NR2F6 seems to reg-
ulate Th17-dependent autoimmunity, but with no apparent 
involvement of RORt (Hermann-Kleiter et al., 2008). It 
required for Th17 induction, whereas the expression of the tran-
scription factors determining Th1, Th2, and regulatory T cell 
differentiation, i.e., T-bet, GATA-3, and FoxP3, was not influ-
enced by PIO (Fig. 2 b), again confirming that PPAR acted 
specifically on the differentiation of Th17 cells. Other transcrip-
tional regulators have been reported to influence Th17 differen-
tiation. Foxp3 has been shown to directly antagonize RORt 
activity, and thus prevent Th17 differentiation (Zhou et al., 
Figure 2.  Selectivity of PPAR for Th17 differentiation. (a) CD4+ T cells were subjected to Th1, Th2, Th17, and regulatory T cell differentiation pro-
tocols, as described in the Materials and methods section, and the influence of RA and PIO on the induction of lineage markers was determined by flow 
cytometry and analyzed as described in Materials and methods. (b) CD4+ T cell differentiation was induced as described in Materials and methods, and the 
influence of PIO on expression of the lineage-determining transcription factors T-bet, GATA-3, RORt, and Foxp3 was determined by quantitative real-
time PCR and normalized to -actin levels after 48 h. Data in a and b are representative of at least three independent experiments.JEM VOL. 206, September 28, 2009  2083
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illustrate  the  dynamic  range  of  PPAR-mediated  control  of 
Th17 differentiation. We substantiated the influence of PPAR 
activation on RORt expression using reporter mice, which 
express GFP under control of the RORc(t) promoter (Lochner 
et al., 2008). In such T cells, we observed that PIO strongly 
reduced TGF-/IL-6–mediated GFP-expression (Fig. 3 b). 
Importantly, both the frequency of GFPpos T cells and the 
mean fluorescence intensity of GFP-expressing T cells were 
reduced by PIO (Fig. 3, b and c). These results indicated that 
most CD4+ T cells failed to express RORt under the influ-
ence of PPAR activation, thus giving rise to less Th17 cells. 
Furthermore, the decreased mean fluorescence intensity of 
GFP in PIO-treated RORc(t) reporter T cells (Fig. 3 c) re-
vealed that upon PPAR activation there was less GFP, i.e., 
RORt, on a per cell basis, suggesting that PPAR reduced 
RORt transcription on a single-cell level.
can therefore be concluded that several receptors are involved 
in the T cell–intrinsic control of Th17-responses, but that the 
molecular pathways involved in these processes are distinct. 
Even among the family of PPARs, the regulatory effect on 
Th17 differentiation is not a general feature, as lack of PPAR 
in T cells did not result in altered IL-17 expression levels 
(Dunn et al., 2007).
PPAR inhibits Th17 differentiation by controlling  
RORt induction
We next evaluated whether PPAR influenced RORt ex-
pression in T cells. In PPARKO T cells, we observed en-
hanced cytokine-induced RORt induction compared with 
PPARWT T cells (Fig. 3 a). The suppressive effect of PPAR 
activation by PIO on the one hand and the increased ex-
pression of RORt in PPARKO T cells on the other hand 
Figure 3.  PPAR inhibits Th17 differentiation by controlling RORt induction. (a) Th17 differentiation from PPARKO and wild-type T cells was 
induced as described in Materials and methods; RORt expression was determined by quantitative real-time PCR and normalized to -actin levels. (b and c) 
CD4+ T cells from Rorc(t)-GFPTG reporter mice were treated with PIO, and Th17 differentiation was induced. After 14 h, GFP expression was assessed  
by flow cytometry and analyzed for frequency of GFPpos cells (b) and for MFI of GFP-expressing cells (c). One out of three independent experiments is 
shown. (d) PPAR was recombinantly expressed (Fig. S3 a), and interaction of recombinant PPAR with the murine RORt promoter was determined by 
surface plasmon resonance analysis. Sensograms show the binding of indicated concentrations of PPAR at either the RORt promoter or the murine 
AP2 promoter containing a bona fide PPRE site as positive control; shown are a representative sensogram (left) and a quantitative analysis (right). The bar 
graph shows mean ± SEM from three independent experiments. (e) Signal-dependent clearance of SMRT from the RORt promoter is prevented by PIO. 
ChIP experiments were performed for SMRT in mock-treated CD4+ T cells and in CD4+ T cells stimulated with TGF-/IL6 in the presence or absence of PIO. 
ChIP assay was performed with SMRT or IgG for control of specificity. Immunoprecipitated DNA was analyzed by quantitative PCR using primers specific 
for the RORt promoter; as control, binding of SMRT to a nonrelated DNA control (exon 1 of the ROR gene) was investigated and set as 1. Two indepen-
dent experiments were performed, and mean results ± SEM are shown.2084 PPAR INHIBITS TH17 DIFFERENTIATION | Klotz et al.
Figure 4.  PPAR in T cells controls CNS autoimmunity and restricts Th17 differentiation in vivo. (a) MOG-EAE was induced in CD4-PPARKO 
mice and CD4-PPARWT littermates (n = 8 per group, 3 experiments), and the clinical disease score was assessed daily. (b) In a separate experiment, mice JEM VOL. 206, September 28, 2009  2085
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were sacrificed at indicated time points and mononuclear cells derived from the CNS of KO mice and WT littermates (± PIO) were analyzed by flow cytom-
etry. Mean results from n = 4 animals per group and time point ± SEM are shown; data are from 2 experiments. (c) CD4+ T cells from spleens and CNS of 
each animal were restimulated with MOG35-55-loaded DCs, and numbers of IL-17 and of IFN-–producing cells per 3 × 104 CD4+ T cells were determined 
by ELISpot analysis. Graphs denote mean ± SEM of all animals (8 per group; 3 experiments). (d and e) 106 CD90.2+ OT-II cells were adoptively transferred 
into congenic mice treated with PIO or vehicle alone (w/o Pio), followed by s.c. immunization with OVA/CFA (100 µg OVA/mouse). CD44 and CD62L ex-
pression levels, as well as IL-17A production upon restimulation with PMA/ionomycin, were assessed by flow cytometry at day 4. Six animals per group; 
shown are representative plots and mean results ± SEM, from two experiments.
 
The control of PPAR over RORt transcription led 
us to examine whether the RORt promoter contained a 
bona fide PPAR-binding site (PPRE), which might per-
mit direct interaction of PPAR with the RORt pro-
moter.  Bioinformatic  analysis  did  not  reveal  any  known 
PPRE sequence within the mouse RORt promoter (un-
published data). In addition, we excluded direct interaction 
of PPAR with the RORt promoter by examining the 
binding of recombinant PPAR to the full-length RORt 
promoter using surface plasmon resonance analysis. In con-
trast to strong and specific binding of PPAR to the AP2 
promoter,  which  contains  a  PPRE  site  (Frohnert  et  al., 
1999), we did not observe significant binding to the RORt 
promoter (Fig. 3 d).
The lack of a high-affinity PPAR binding site in the 
RORt promoter raised the possibility that PPAR might 
negatively regulate RORt transcription through a trans-
repression mechanism that does not require direct DNA 
binding. One such mechanism involves the ability of ligand- 
activated PPAR to inhibit signal-dependent clearance of 
NCoR or SMRT corepressor complexes from promoters of 
regulated genes (Pascual et al., 2005; Ghisletti et al., 2009). 
To investigate this possibility, we used chromatin immuno-
precipitation (ChIP) to screen of genomic sequences sur-
rounding  the  RORt  promoter  (unpublished  data)  for 
corepressor binding. These studies revealed the binding of 
the corepressor SMRT, but not NCoR, at the RORt 
promoter in unstimulated mouse CD4+ T cells (Fig. 3 e and 
not  depicted).  Importantly,  stimulation  of  CD4+  T  cells 
with TGF- and IL-6 resulted in rapid and nearly complete 
loss of SMRT from the RORt promoter (Fig. 3 e), indi-
cating that SMRT clearance precedes RORt activation. 
Interestingly,  this  cytokine-induced  clearance  of  SMRT 
from the RORt promoter was prevented by the PPAR 
agonist PIO (Fig. 3 e). These data suggest that the reten-
tion of SMRT results in persistent repression of RORt 
in the presence of activating cytokines, and are consistent 
with prior studies demonstrating that PPAR suppresses 
activation of inflammatory response genes in macrophages 
by preventing NCoR/SMRT turnover (Ghisletti et al., 
2009). Interference of SMRT clearance from the RORt 
promoter thus provides a previously unrecognized mech-
anism  by  which  ligand-activated  PPAR  may  control 
Th17 differentiation in T cells. However, these findings 
do not exclude other mechanisms, such as modulation of 
STAT3 or IRF4 signaling (Nurieva et al., 2007; Huber   
et al., 2008).
PPAR in T cells controls CNS autoimmunity and restricts 
Th17 differentiation in vivo
To analyze whether PPAR is involved in T cell–intrinsic 
control of CNS autoimmunity, we induced EAE in CD4-
PPARKO mice and wild-type littermates. CD4-PPARKO 
mice showed a significantly earlier onset and aggravated dis-
ease course during the initial T cell–dependent phase of dis-
ease until d15 (Fig. 4 a). However, this difference was not 
observed  in  the  effector  phase,  when  disease  activity  is 
mainly determined by a local inflammatory response within 
the  CNS  governed  by  microglial  cells  (Heppner  et  al., 
2005).  Disease  activity  in  CD4-PPARKO  mice  directly 
correlated with the total numbers of infiltrating CD4+ T 
cells in the CNS (Fig. 4 b). Both at the beginning of clinical 
disease activity (day 8), and at the peak of disease in CD4-
PPARKO mice (day 13), we found significantly increased 
total CD4+ T cell numbers in the CNS. Later (day 18) dis-
ease score and T cell influx were not different from wild-
type littermates. As expected, PIO-treated wild-type mice 
exhibited decreased T cell numbers within the CNS at all 
time points investigated (Fig. 4 b). Importantly, at the peak 
of disease in CD4-PPARKO mice, the frequency of MOG35-55 
peptide-specific, IL-17–producing CD4+ T cells in the CNS 
was increased by threefold, which, together with the increase 
in T cell influx, enhanced the numbers of IL-17–producing 
autoreactive T cells within the target organ by nearly five-
fold (Fig. 4, b and c). In contrast, there was no alteration in 
antigen-specific IFN-–producing CD4+ T cells in these 
mice (Fig. 4 c).
The  clinical  symptoms  and  antigen-specific  Th17  re-
sponses in CD4-PPARKO mice both revealed that the ki-
netics of CNS autoimmunity in vivo were modulated by 
PPAR in a T cell–intrinsic fashion. There was pronounced 
accumulation of IL-17–producing T cells in the CNS com-
pared with the spleen in CD4-PPARKO mice (Fig. 4 c), 
which may be caused by guided entry of Th17 cells into the 
CNS. A recent study demonstrated that CCR6-expressing 
Th17 cells function as “pioneer” cells, enabling immune cell 
entry into the CNS at the beginning of CNS autoimmunity 
(Reboldi et al., 2009). In this regard, the control of expres-
sion of both CCR6 and its ligand CCL20 by PPAR activa-
tion (Fig. 1 g) may explain the decreased influx of T cells and 
the reduced disease activity in the CNS of PIO-treated wild-
type mice. The protective effect of PIO on disease activity 
was greatly diminished in CD4-PPARKO mice (Fig. S4 b), 
thus excluding off-target effects that had been reported previ-
ously (Chawla et al., 2001) and further demonstrating that 2086 PPAR INHIBITS TH17 DIFFERENTIATION | Klotz et al.
development, despite its profound effect on Th17 differenti-
ation, lends support for a key but not exclusive role of Th17 
cells in CNS inflammation, as previously reported (Yang   
PPAR expression in T cells was required for full protective 
effect of PIO on CNS autoimmunity. The observation that 
PPAR activation in vivo did not entirely protect from EAE 
Figure 5.  PPAR selectively controls Th17 differentiation in T cells from HCs and MS patients. CD45RA+ CD4+ T cells from HC (n = 5) and from 
relapsing-remitting MS patient (n = 7) were treated with PIO and stimulated as described in Materials and methods. (a) IL-17A+ cells from HC and MS-
patients after restimulation with PMA/ionomycin were assessed by flow cytometry. (b) IL-17A and IFN- secretion were determined by ELISA. Graphs 
show mean percentages ± SEM from the separate experiments (n = 7). (c) CD4+ T cells were activated as in a, and expression of IL-17F, IL-21, IL-22, and 
IL-23R was measured by real-time RT-PCR normalized to -actin levels. (d) CD4+ T cells were stimulated as described, and expression of RORt, T-bet, and 
GATA-3 after 72 h was measured by real-time PCR and normalized to -actin levels. (c and d) One representative dataset out of three is shown.JEM VOL. 206, September 28, 2009  2087
BRIEF DEFINITIVE REPORT
et al., 2009). The persistent Th1 responses, which were not 
altered by PPAR activation, may explain persistent disease 
activity, despite diminished Th17 responses.
As we also observed a significant increase in antigen-spe-
cific Th17 cell numbers in the spleen in CD4-PPARKO 
mice at the peak of disease (Fig. 4 c), we next asked whether 
PPAR influenced Th17 differentiation in vivo at early time 
points. To this end, we adoptively transferred CD90.2+ CD4+  
T cells from OT-II mice, followed by immunization with 
OVA in CFA. Importantly, PIO treatment of these mice 
strongly interfered with the expression of activation markers 
(Fig. 4 d) and IL-17 production (Fig. 4 e) by the adoptively 
transferred T cells 4 d after immunization; this persisted for 
longer than 4 d (day 7; not depicted), demonstrating that PPAR 
controls antigen-specific Th17 differentiation in vivo.
Collectively, the entire range of PPAR-sensitive control 
of Th17 differentiation in vivo and CNS autoimmunity is 
reflected by the combination of pharmacological PPAR ac-
tivation on the one hand and by the absence of PPAR- 
activity in CD4-PPARKO mice on the other hand.
PPAR selectively controls Th17 differentiation in T cells 
from healthy controls (HCs) and MS patients
The protective effects of PPAR on both clinical manifesta-
tion and Th17-responses during EAE prompted us to inves-
tigate  whether  T  cells  from  HCs  and  MS  patients  were 
susceptible to treatment with PPAR agonists. Again, we fo-
cused on the effect of PPAR activation on T cells by using 
direct stimulation with TGF-/IL-21 in the absence of anti-
gen-presenting cells. Pharmacologic PPAR activation re-
duced the frequency of IL-17A–producing CD45RA+ CD4+ 
T cells both in HC and MS patients (Fig. 5 a). Although in 
our experiments there was no apparent difference in Th17 
differentiation between HC and MS patients in vitro, it is 
important to note that PIO-treatment was equally effective 
in potent suppression of IL-17A release from T cells (Fig. 5 b). 
Moreover, no influence of PIO was observed during IFN- 
production (Fig. 5 b). Pharmacologic PPAR activation pre-
vented Th17 differentiation, as demonstrated by diminished 
expression of the Th17 markers IL-17F, IL-21, IL-22, and 
IL-23R upon PIO treatment (Fig. 5 c). Importantly, the spe-
cific effect of PPAR activation on Th17 induction in human 
CD4+ T cells was further illustrated by selective regulation of 
RORt expression, whereas T-bet and GATA-3 expression 
were not altered by PIO (Fig. 5 d).
In summary, we identify PPAR as a defined molecular 
target to selectively modulate Th17 differentiation in a T cell–
intrinsic fashion, which opens up new possibilities for specific 
immunointervention in Th17-mediated autoimmune diseases 
such as MS.
MATERIALS AND METHODS
Mice. CD4-specific PPAR knockout mice with the genotype PPARfl/fl 
CD4-Cre+/ (i.e., CD4-PPARKO mice) were generated by crossing 
PPARfl/fl mice (He et al., 2003) with CD4-Cre+/ transgenic mice express-
ing Cre recombinase under control of the CD4 enhancer/promoter/silencer 
(Lee et al., 2001). Expression of Cre recombinase in CD4-expressing T cells 
leads to recombination at two loxP sites flanking exons two and three of the 
PPAR gene, thus resulting in a T cell–specific PPAR knockout (Fig. S1). 
We did not observe any alteration in immune cell frequencies in these mice 
(Fig. S1). CD90.2+ CD4-TCR transgenic OT II mice specific for the pep-
tide ova323-339, BAC-transgenic Rorc(t)-GFPTG mice, and C57BL/6 mice 
(Charles River Laboratories) were maintained under specific pathogen–free 
conditions. All animal experiments were performed according to the guide-
lines of the animal ethics committee and were approved by the government 
authorities of Nordrhein-Westfalen, Germany.
Cell culture and adoptive cell transfer. PBMCs were obtained from the 
peripheral blood of healthy volunteers or from patients with clinically defi-
nite relapsing-remitting MS according to the McDonald criteria, approved 
by the local Ethics Committee. CD4+CD45RA+CD45ROCD25 T cells 
were isolated by immunomagnetic cell separation using an AutoMACS 
(Miltenyi  Biotec)  and  stimulated  with  plate-bound  1.5  µg/ml  CD3   
antibody (OKT3), 1 µg/ml CD28 antibody (28.2), 2.5 ng/ml TGF- 
(R&D Systems) and 12.5 ng/ml IL-21 (Cell Systems) for 7 d in serum-free 
X-VIVO 15 medium (Biowhittaker; Yang et al., 2008). 10 µM PIO (Enzo 
Biochem, Inc.) was added when indicated. Mouse splenic CD4+ T cells 
were  isolated  by  immunomagnetic  separation  using  CD4-MACS  beads 
(Miltenyi Biotec) and stimulated with plate-bound 4 µg/ml CD3 antibody 
(145-2C11) and 4 µg/ml CD28 antibody (3751) together with 5 ng/ml 
TGF- and 20 ng/ml IL-6 (PeproTech) for Th17 differentiation; with IL-
12 (10 ng/ml) for Th1 differentiation; with IL-4 (10 ng/ml) for Th2 differ-
entiation or with TGF- alone (5 ng/ml) for regulatory T cell differentiation. 
In one experiment, MACS-isolated splenic DCs from B6 mice were cocul-
tured with T cells in the presence of antigen (10 µg/ml ova323-339). The en-
dogenous PPAR agonist 13s-HODE (Cayman Chemicals) was used at a 
concentration of 10 µM. All-trans RA (Sigma-Aldrich) was used at a 1 µM 
concentration. TCR transgenic CD4+ T cells from OTII mice bearing the 
congenic marker CD90.1+ were isolated and 106 cells were adoptively trans-
ferred by bolus i.v. injection in 200 µl PBS into wild-type CD90.2+ con-
genic mice.
EAE.  EAE  was  induced  by  s.c.  injecting  50  µg  MOG35-55  peptide 
(BIOTREND) emulsified in CFA (Difco) with 8 mg/ml heat-inactivated 
Mycobacterium tuberculosis and two i.p. injections of 200ng Bordetella pertussis 
toxin (List Biologicals) on days 0 and 2. Clinical assessment of EAE was per-
formed daily using a scale ranging from 0 to 6: 0, clinically normal; 1, re-
duced  tone  of  tail;  2,  ataxia  and/or  slight  hind-limb  paresis;  3,  severe 
hind-limb paresis; 4, hind limb plegia; 5, tetraparesis; 6, moribund/dead ani-
mals. Cell analysis from spleens and CNS was performed as indicated.
Real-time RT-PCR. Cells were washed with ice-cold PBS, and RNA 
extraction was performed using the RNeasy mini kit (QIAGEN) according 
to the manufacturer’s protocol. Reverse transcription of RNA was per-
formed with SuperScript III (Invitrogen). cDNA was analyzed using FAM-
labeled  TaqMan  probes  obtained  from  Applied  Biosystems  and  used 
according to the manufacturer’s recommendations. mRNA expression levels 
of RORt, T-bet, GATA-3, and Foxp3, as well as the Th17 markers IL-
17A, IL17F, IL-21, IL-22, and IL-23R, were assessed using gene-specific 
primers. Gene expression was assessed in triplicates and normalized to -
  actin. Amplification of cDNA was performed on an AbiPrism 7900 HT cycler 
(Applied Biosystems).
Cytokine detection. Mouse IL-17A and Foxp3 protein expression were 
examined by intracellular staining according to the manufacturer’s protocol. 
MOG-specific  IL-17  and  IFN-  production  was  analyzed  by  specific 
ELISpot assays according to the manufacturer’s procedures (R&D Systems), 
and spot numbers were counted with an automated ELISpot reader (BIO-
READER-2000). Human IL-17A and IFN- protein levels from cell cul-
ture supernatants were determined by ELISA (R&D Systems).2088 PPAR INHIBITS TH17 DIFFERENTIATION | Klotz et al.
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ChIP experiments. ChIP assays were performed as previously described 
(Pascual et al., 2005). Th17 differentiation was induced for the indicated 
time points before cross-linking for 10 min with 1% formaldehyde. Anti-
SMRT (ABR) or control rabbit IgG (Santa Cruz Biotechnology, Inc.) were 
used for immunoprecipitation. A 150-bp region of the RORt promoter 
was amplified spanning the most proximal transcription start site. Quantita-
tive PCR was performed with SYBR-GreenER (Invitrogen) and analyzed 
on a 7200 real time PCR system (ABI).
Surface plasmon resonance analysis. 6xHIS-PPAR was recombinantly 
expressed in the bacterial strain Escherichia coli BL21, eluted, and desalted us-
ing a PD-10 column and 10% glycerol in PBS. The promoter sequences of 
mouse RORt and mouse AP2 were amplified by PCR using the oligo-
nucleotides (5-GCTTCCCAATGGACACTTGCAAG-3 and 5-AGGA-
CAGCACACAGCTGGCAGTGG-3 for RORt; and 5-TCTAGAAG-
GAAGAACCAGGG-3 and 5-AGGCAGAAATGCACATTTCACC-3 
for AP2). For each reaction, one primer was biotinylated at the 5 end. As 
negative control, a 2-kb fragment of the mouse mannose receptor was am-
plified. For SPR analysis of promotor binding, a Biacore 3000 (GE Health-
care) was used. In brief, 700–1,000 RU of 5-biotinylated variants of the re-
spective dsDNAs were immobilized on the surface of a SA-sensorchip (GE 
Healthcare) according to the manufacturer’s instructions. As negative con-
trol, 2 kb of the mouse mannose receptor was used. PBS (pH 7.3) was used 
as running buffer, and the regeneration of the surface was accomplished by 
injecting 1 M Urea for 30 s. All measurements were done at a flow rate of 
30 µl/min, and protein injections at indicated concentrations were con-
ducted for 2 min using the “inject” mode. Measurements were done in the 
presence of 0.001 mg/ml heparin to reduce unspecific binding.
Online  supplemental  material.  Fig.  S1  shows  the  Th17  differenta-
tion of highly purified naive CD4+ T cells. Fig. S2 shows the generation 
of  T  cell–specific  PPAR  knockout  mice  and  phenotypic  characteriza-
tion of immune cells. Fig. S3 shows the purification of recombinantly ex-
pressed  full-length  murine  PPAR;  surface  plasmon  resonance  analysis 
of PPAR-binding to PPRE-oligonucleotides; and effect of PPAR on 
SMRT-binding to the RORt promoter in the absence of Th17 induc-
ing  conditions.  Fig.  S4  shows  the  effect  of  the  CD4-Cre  transgene  on 
EAE disease course and the absence of a protective PIO effect in CD4-
PPARKO mice. Online supplemental material is available at http://www 
.jem.org/cgi/content/full/jem.20082771/DC1.
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